Phase 4 N=21 Randomized Diagnostic

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT01502787 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2014

Primary outcome: Primary: Forearm Blood Flow — 96; 105 ml/min

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Metoprolol succinate (Drug); Nebivolol (Drug); Forearm blood flow (Procedure); Microneurography (Procedure); Rhythmic handgrip exercise (Procedure); Lower body negative pressure (Procedure); Angiotensin II (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Texas Southwestern Medical Center
Primary completion: Jun 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Forearm Blood Flow	96; 105	—
SECONDARY Blood Pressure During Exercise	101; 103	—
SECONDARY Blood Pressure During Angiotensin II Infusion	114; 113	—

Summary

The purpose of this study is to determine if Nebivolol a) attenuates the angiotensin II (Ang II)-induced increase in oxidative stress, thereby attenuating Ang II-induced vasoconstriction; and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients.

Eligibility Criteria

Inclusion Criteria

Stage I hypertension (140-159/90-99 mmHg)
Men and women age 18-65

Exclusion Criteria

Congestive heart failure or coronary artery disease
Blood pressure averaging >159/99 mmHg or resting heart rate 1.4 mg/dL
Asthma or chronic obstructive pulmonary diseases
Left ventricular hypertrophy by echocardiography or ECG
Pregnancy
Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin
Any history of substance abuse (other than tobacco)
Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)
History of symptomatic bradycardia or heart block

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01502787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.